Leading Indian drugmaker Sun Pharmaceutical Industries (BSE: 524715) has reported financials for the full year ending March 31, 2023 (FY23).
Gross sales for the year came in at 432,789 million rupee ($5.24 billion), an increase of 12.6% over the previous year.
India formulation sales were 136,031 million rupees, up 6.6% over the previous year. US formulation sales were $ 1,684 million, up 10.3%, and global specialty sales were $871 million, up 29%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze